DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Beloranib is an investigational drug.
There have been 8 clinical trials for Beloranib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Prader-Willi Syndrome, Overweight, and Obesity. The leading clinical trial sponsors are Zafgen, Inc. and [disabled in preview].
There are seventy-four US patents protecting this investigational drug and eight hundred and sixteen international patents.
Recent Clinical Trials for Beloranib
|An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus||Zafgen, Inc.||Phase 2|
|Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome||Zafgen, Inc.||Phase 3|
|An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury||Zafgen, Inc.||Phase 2|
Top disease conditions for Beloranib
Top clinical trial sponsors for Beloranib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Beloranib||Get Started Free||METAP2 inhibitors and methods of treating obesity||SynDevRx, Inc. (Cambridge, MA)||Get Started Free|
|Beloranib||Get Started Free||Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions||Emory University (Atlanta, GA) The United States Geovernment represented by the United States Department of Veterans Affairs (Washington, DC)||Get Started Free|
|Beloranib||Get Started Free||Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome||Essentialis, Inc. (Redwood City, CA)||Get Started Free|
|Beloranib||Get Started Free||Anti-Laminin4 antibodies specific for LG4-5||PROTHENA BIOSCIENCES LIMITED (Dublin, IE)||Get Started Free|
|Beloranib||Get Started Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||Get Started Free|
|Beloranib||Get Started Free||Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk||ELCELYX THERAPEUTICS, INC. (San Diego, CA)||Get Started Free|
|Beloranib||Get Started Free||ACC inhibitors and uses thereof||Gilead Apollo, LLC (Foster City, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Beloranib||Argentina||AR095828||2033-04-10||Get Started Free|
|Beloranib||Australia||AU2014250983||2033-04-10||Get Started Free|
|Beloranib||Brazil||BR112015025892||2033-04-10||Get Started Free|
|Beloranib||Canada||CA2908993||2033-04-10||Get Started Free|
|Beloranib||China||CN105431426||2033-04-10||Get Started Free|
|Beloranib||Denmark||DK2984085||2033-04-10||Get Started Free|
|Beloranib||Eurasian Patent Organization||EA033912||2033-04-10||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|